Verve Therapeutics Inc. (VERV)
6.33
0.00 (0.00%)
At close: Mar 03, 2025, 12:16 PM
Verve Therapeutics Income Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
| Revenue | 32.33M | 11.76M | 1.94M | n/a | n/a | n/a |
| Cost of Revenue | n/a | 5.46M | 6.71M | 3.38M | 1.33M | 106K |
| Gross Profit | 32.33M | 6.3M | -4.77M | -3.38M | -1.33M | -106K |
| Operating Income | -228.66M | -223.12M | -165.69M | -87.07M | -40.63M | -13.64M |
| Interest Income | n/a | n/a | 6.87M | 142K | 162K | 278K |
| Pretax Income | -198.36M | -199.79M | -157.33M | -120.31M | -45.7M | -19.3M |
| Net Income | -198.71M | -200.07M | -157.39M | -118.64M | -45.54M | -19.02M |
| Selling & General & Admin | 56.65M | 49.94M | 37.53M | 18.86M | 5.26M | 2.5M |
| Research & Development | 204.35M | 184.95M | 130.09M | 68.2M | 35.37M | 11.14M |
| Other Expenses | n/a | n/a | 1.49M | -33.39M | -5.24M | -5.93M |
| Operating Expenses | 260.99M | 234.88M | 167.63M | 87.07M | 40.63M | 13.64M |
| Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 260.99M | 234.88M | 167.63M | 87.07M | 40.63M | 13.64M |
| Income Tax | 349K | 275K | 53K | -1.68M | -162K | -278K |
| Shares Outstanding (Basic) | 84.23M | 64.18M | 54.02M | 48.51M | 48.22M | 48.22M |
| Shares Outstanding (Diluted) | 84.63M | 64.18M | 54.02M | 48.51M | 48.22M | 48.22M |
| EPS (Basic) | -2.36 | -3.12 | -2.91 | -2.45 | -0.94 | -0.39 |
| EPS (Diluted) | -2.35 | -3.12 | -2.91 | -2.45 | -0.94 | -0.39 |
| EBITDA | -228.66M | -217.67M | -162.88M | -85.53M | -39.3M | -13.54M |
| Depreciation & Amortization | n/a | 5.46M | 6.71M | 3.38M | 1.33M | 106K |